Yeast-based assays have been developed to detect inactivating mutations in human genes, but these assays generally rely on the human protein having a biological function in yeast. We describe a simple method to detect mutations by virtue of their ability to abolish a proteinprotein interaction in the yeast two-hybrid assay. By the use of direct recombinational cloning in yeast of a reverse transcription-PCR product followed by a simple growth selection this method distinguished both homozygous and heterozygous mutations in the p53 tumor suppressor gene. This approach should be applicable to many human genes whose encoded proteins have suitable partners in the two-hybrid assay.
INTRODUCTION
As more genes are identified in which mutations cause human disease, rapid and inexpensive assays to detect these mutations have become essential. Many current methods are limited in their practicality or applicability. For example, DNA sequencing by traditional methodology, although it provides the most complete data, is expensive and has difficulty in detecting heterozygosity. New developments, such as sequence determination by hybridization-based methods with oligonucleotide arrays (1), should allow high throughput sequencing at reduced cost, but are not yet widely available. Furthermore, sequencing cannot distinguish between polymorphisms and mutations that affect function except by comparison with previously characterized mutations. Approaches that rely on DNA conformation in non-denaturing polyacrylamide gels, heteroduplex analysis or allele-specific oligonucleotides are also limited by their labor intensity and inability to identify many mutations of interest.
Simple assays have been described that use the yeast Saccharomyces cerevisiae to assess the biological activity of genes associated with human disease. In particular, the functional analysis of separated alleles in yeast (FASAY) assay (2) uses rapid cloning into yeast of the cDNA for a particular gene to allow analysis of a pool of transformants for biological function. In this procedure co-transformation of a PCR product with a linearized vector containing the same sequences as the ends of the PCR product results in repair of the vector by homologous recombination (see for example Fig. 1A) . If the vector to be repaired is a yeast expression vector, the outcome is a set of transformants each of which produces the human protein encoded by one of the DNA molecules from the PCR. The transformants are then subjected to an assay to determine whether the encoded protein is functional. Because this assay examines activity in colonies expressing a protein corresponding to an individual mRNA molecule, heterozygosity is easily observed; because it assays activity, only relevant mutations are detected. In its original description this assay depended on the human gene having a biological activity in yeast, which is not the case for many genes. In addition, mutant proteins may display different biological activities in human and yeast cells (3) . A similar yeast assay has been developed to detect protein truncation (4), useful for genes such as APC and BRCA1 that are highly susceptible to truncating mutations, but unable to detect non-truncating missense mutations or in-frame deletions.
The two-hybrid system (5) detects protein-protein interactions in yeast by the interaction of a protein fused to a DNA binding domain with a protein fused to a transcriptional activation domain. This method has been used for identification of proteins that bind to many human proteins, including several implicated in disease. Furthermore, mutations that are associated with a disease state have in some cases been found to correlate with encoded proteins that are defective in binding to another protein (6, 7) . We describe here a use of the two-hybrid system to determine whether a p53 allele encodes a protein able to interact with a protein that binds only to wild-type p53. This method expands the FASAY approach to include the increasing number of human genes that encode proteins with appropriate interactors in this assay, providing a rapid initial screening for mutant alleles.
RESULTS
The overall strategy is described here briefly and in more detail below. It begins with the cloning of a PCR product corresponding to p53 mRNA into a DNA binding domain vector (Fig. 1A) . The two-hybrid interaction of wild-type p53 with the p53-interacting protein 53BP1 (6) results in transcription of the HIS3 reporter gene, whereas a mutant p53 that fails to bind 53BP1 does not activate this reporter gene (Fig. 1B) . Colonies are patched onto plates that select only for the presence of the two-hybrid plasmids (Fig. 1C , left) and replica-plated on to plates that indicate whether the two-hybrid interaction occurs (Fig. 1C, right) . A representative example of the results is shown in Figure 1D .
In order to enable one-step cloning of p53 alleles we generated a Gal4 DNA binding plasmid, pGBT53GAP, which contains two 120 bp segments of DNA encoding p53 flanking a unique restriction site; these encode residues 73-113 and 353-393. Upon linearization by digestion at this site the plasmid was unable to transform yeast efficiently. , resulting in transcription of the HIS3 reporter gene, whereas the right panel shows a mutant p53 unable to interact with 53BP1 and, consequently, no HIS3 expression. Gal4 ACT, Gal4 transcriptional activation domain; GAL UAS, upstream activation sequence for the galactose genes, which binds Gal4; HIS3, yeast HIS3 gene which is activated by two-hybrid interaction. (C) Transformants were grown as patches on medium that selects only for the presence of the plasmids and replica-plated to one that selects for two-hybrid activity. (D) Transformants derived from sample FA9 and controls were patched onto a -Leu -Trp plate and replica-plated to a -Leu -Trp -His +3AT plate. Colonies directly above or below a plus (+) sign are wild-type p53 controls; colonies directly above or below a minus (-) sign are mutant (R175H or R273H) controls. The controls were placed at all four corners to control for unevenness in replica plating.
in circularization by recombination (Fig. 1A) . Transformations carried out in the presence of the PCR product resulted in at least a 20-fold and often a 50-to 100-fold increase in the number of transformants (data not shown). The p53-interacting protein 53BP1 was encoded as an activation domain hybrid by plasmid pSEBP1. We transformed the yeast reporter strain Y153 (8) , which contains a HIS3 gene under regulation of Gal4 binding sites. This strain produces a low level of His3 protein in the absence of any plasmids. However, His3 activity can be inhibited using 3-amino-1,2,4-triazole (3AT). Thus at 25 mM 3AT it was possible to achieve a level of stringency such that only a wild-type, or nearly wild-type, level of interaction between p53 and 53BP1 was sufficient to yield growth of transformants in the absence of histidine (Fig. 1B, left) .
Seven clinical samples were independently evaluated by the transcriptional activation assay (9) and by the two-hybrid interaction assay. The transcriptional activation assay is a functional assay that relies on the ability of the p53 protein to behave as a site-specific transcription factor in yeast. p53 cDNA is cloned by gap repair into a yeast expression vector by transformation of a yeast strain carrying an integrated ADE2 reporter gene under control of a p53-responsive promoter. The utility of the yeast ADE2 gene as reporter is that Ade + colonies that result from wild-type p53 expression are white, whereas Ade -colonies from mutant p53 expression are red, because of accumulation of an intermediate in adenine metabolism in ade2 yeast. RNA was isolated from cell lines derived from a malignant melanoma and other tumors and from frozen tissue of a head and neck tumor and reverse transcription-PCR (RT-PCR) with p53 primers was performed as described (9) . Yeast yIG397, containing the ADE2 reporter gene, was co-transformed with a linearized p53 expression vector that requires gap repair to reconstitute a functional p53 coding sequence and the ability of the p53 proteins derived from the seven samples to activate ADE2 transcription was determined (9; Table 1 ). This assay indicated that one sample is derived from an individual who is homozygous wild-type, four from individuals who are homozygous mutant and two from individuals who are heterozygous.
The seven RT-PCR products, blindly coded, were used to co-transform yeast Y153 with linearized pGBT53GAP (Fig. 1A) . The yeast strain contained the plasmid pSEBP1 encoding the Gal4 activation domain fused to 53BP1. Transformants were selected on plates lacking leucine and tryptophan, selecting for the LEU2 and TRP1 genes present in pSEBP1 and pGBT53GAP respectively. Control transformations included the linearized vector with no insert with a PCR product derived from wild-type p53 or with PCR products derived from p53 mutants R175H or R273H, neither of which can bind 53BP1. Colonies from each transformation were patched onto -Leu -Trp plates and replica-plated onto medium lacking histidine and containing 3AT to identify transformants in which the two-hybrid interaction occurred (Fig. 1C) . Samples were scored to determine the ratio of transformants able to grow on the two-hybrid selective medium (i.e. His + ) to the total number of transformants (Fig. 1D) . Of the seven samples, six were in agreement with the transcriptional assay, while the seventh, FA10, was interpreted to be homozygous mutant by transactivation and homozygous wild-type by two-hybrid assay (Table 1) . FA10 was sequenced and found to be homozygous for the mutation R267W, found in other human tumors. This mutation abolishes the ability of p53 to activate transcription in yeast but not to bind 53BP1, a property observed previously with other p53 mutants (10); other p53 mutations eliminate protein binding without affecting transactivation activity (10) . For the six samples that yielded consistent results in the two assays confirmation of the mutations inferred from the transactivation and two-hybrid assays could also be obtained by DNA sequence analysis. 
DISCUSSION
We present in this report a simple yeast-based assay to determine whether a mutation that affects protein function is present in a gene. This two-hybrid assay should prove to be a useful additional means for screening of human genes implicated in disease. It has some disadvantages, including the inability to detect all point mutations of interest or alleles present in a heterozygous state with the wild-type that result in loss of expression of the protein.
The assay cannot be used if an interacting protein is not available or if the interaction is not sensitive to the mutant state of the protein that is to be tested. However, this method is inexpensive and rapid to perform and requires no DNA purification, ligation or bacterial transformation steps or any equipment beyond that necessary for simple yeast procedures. The screen detects heterozygosity at the RNA level, avoids identification of irrelevant mutations and should be able to identify mutant proteins even if the clinical sample is derived from a mixture of wild-type and mutant tissues. For large proteins implicated in disease, small domains may exist that are responsible for binding to different proteins, such that a panel of two-hybrid interactions could be used in the assay. For example, domains of the large Brca1 (1863 residues) and Brca2 (3418 residues) proteins implicated in human breast cancer susceptibility interact by two-hybrid analysis with a RING domain-containing protein (11) and Rad51 protein (12) respectively. However, as functional assays in yeast, such as the one described here, do not provide the site of mutation, these simple screens may prove most useful as initial assays, with results that indicate the presence of a mutation being followed up by additional methods to yield more precise mutational identification.
MATERIALS AND METHODS

Plasmids and strains
Plasmid pSEBP1 (denoted pSE1107-A16) and plasmids containing wild-type p53 and mutant alleles R175H and R273H have been described (6) . Plasmid pSS16 was used to clone p53 by homologous recombination for transcriptional activation assays (2) . Plasmid pGBT53GAP was created by ligating fragments generated by PCR into pGBT9 (13) digested with EcoRI and BamHI. The fragment encoding human p53 amino acids 73-113 was flanked with EcoRI and Ecl136II sites and the fragment encoding human p53 amino acids 353-393 was flanked with Ecl136II and BamHI sites. When digested with Ecl136II the linearized plasmid has blunt ends and 120 nt of homology to the 5′-and 3′-ends of the human p53 open reading frame, omitting the transcriptional activation domain present in the N-terminal 73 amino acids. The yeast strains used in this assay were Y153 (8) and yIG397 (9) .
Sample preparation and transcriptional activation assay
Clinical tumor samples were received at OncorMed and cultured. RNA isolation and RT-PCR were performed as described (9), using proofreading Pfu polymerase (Stratagene) with primers that amplify the entire p53 open reading frame.
Transcriptional activation assays were performed as described (9) . Yeast strain yIG397 was co-transformed with linearized pSS16 (digested with HindIII and StuI), unpurified RT-PCR product and carrier DNA by a lithium acetate procedure (2) and plated onto synthetic minimal medium minus leucine (SD -Leu) (14) plus adenine (2.5-5 µg/ml) and incubated until the red color indicating ade2 yeast was clearly visible. Between 200 and 500 colonies were scored in each assay. Plasmids encoding mutant p53 and the RT-PCR product from a cell line known to be mutant for p53 were used as negative controls in the assay.
Two-hybrid assay
Yeast strain Y153 containing plasmid pSE53BP1 was grown overnight to stationary phase in 5 ml SD -Leu and transformed according to the 'one-step' protocol (15) . Pelleted yeast were resuspended in one-step buffer (40% PEG, 200 mM lithium acetate, 100 mM DTT), and 10-50 µg carrier DNA, 125 ng linearized pGBT53GAP vector and 150-500 ng RT-PCR product were added. Control transformations were included in each assay, without insert and with PCR-derived inserts from wild-type p53 and the p53 mutants R175H and R273H. The yeast suspensions were incubated at 45_C for 30 min and plated onto SD -Leu -Trp. After colonies had grown they were picked and patched onto SD -Leu -Trp, along with controls for wild-type and mutant p53. These plates were replica plated onto SD -Leu -Trp -His + 25 mM 3AT to select for two-hybrid activation. Plates were scored for the ability of transformants to grow under selective conditions after 3-5 days at 30_C.
Plasmid recovery and DNA sequencing
Plasmids containing p53 alleles were rescued from yeast using a glass bead lysis procedure (16) and transformed into Escherichia coli. Purified miniprep DNA was sequenced using a dye-terminator cycle sequencing kit (Applied Biosystems) with an ABI model 377 DNA Sequencer.
